VACCINES IN TIMES OF

PANDEMIA

PROF. DR. ARTURO REYES-SANDOVAL

DIRECTOR GENERAL
INSTITUTO POLITECNICO NACIONAL
A YEAR AGO AND BETWEEN 2004-2020.
 150 100 trials using
Jenner
Clinical Trials
Institute’s own
In 10 years vaccines

Malaria
2,000 TB
HIV
HPV
Volunteers per MERS
Ebola
Year Flu
Zika
18,000 COVID Dengue
Chikungunya
 R&D / Phase 2b
Phase Ia Phase Ib
Pre-clinical GMP Trial
Trial Trial
Chagas
Dengue Zika
Chikungunya Chikungunya
Mayaro Malaria
Zika Zika
Yellow Fever

Reyes Group
Vaccine pipeline
2018 UK MEXICO
 INSTITUTO POLITÉCNICO NACIONAL

THE MOST IMPORTANT HIGHER EDUCATION INSTITUTION IN

MEXICO DEDICATED TO SCIENCE AND TECHNOLOGY
 IPN
Has presence all over Mexico

90 211,839
Students
Academic Units
High School
Undergraduate
Graduate
16,000
Academics
VACCINES IN TIMES OF PANDEMIA
VACCINES IN TIMES OF PANDEMIA
 CORONAVIRUS STRUCTURE

COVID19 Vaccines are designed to

Induce immune responses to:

• Spike

• RBD

• Whole virus
• Attenuated
• Inactivated

Reprinted from "Human Coronavirus Structure", by BioRender, August 2020, retrieved from https://app.biorender.com/biorender-templates/figures/5e99f5395fd61e0028682c01/t-5f21e90283765600b08fbe9d-
human-coronavirus-structure Copyright 2020 by BioRender.
 COVID19 VACCINES:
MECHANISM OF ACTION

COVID vaccines
mechanism of action
is mainly through
induction of
neutralizing antibodies
vs
Spike
or
RBD

Prepared in biorender.com
There are 8
types of
COVID
vaccines:
Virus Viral Genetic Proteins
vectors Material
 WHO VACCINE FOLLOW UP –
JAN 2021

66.1% 15.5% 9.2 % 5.97% 3.2 %

https://www.theguardian.com/world/ng-interactive/2020/aug/13/covid-vaccine-tracker-when-will-we-have-a-coronavirus-vaccine
 WHO VACCINE FOLLOW UP –
JAN 2021

https://www.nytimes.com/interactive/2020/science/coronavirus-vaccine-tracker.html
https://www.nytimes.com/interactive/2020/science/coronavirus-vaccine-tracker.html
THE LEADING COVID-19 VACCINES
 NATIONAL VACCINATION STRATEGY IN MEXICO

EXPECTED DOSES FOR 2021: 179,063,050

CALENDAR FOR VACCINE DELIVERY
Doses: 60,277,500
Vaccinated people: 30,138,750

26’408,699

35’000,000

24’000,000

2’900,000

6’472,800
77’410,000
Thanks to Dr. Celia Alpuche
VACCINES ARE ARRIVING IN MEXICO
IN STEPWISE MANNER

Thanks to Dr. Celia Alpuche

 CNCTI-Vaccines
1. Science to support government decisions
2. Close collaboration between CONACyT and the Ministry of Health
3. Strategic plan to identify most promising international vaccines and support developments
in Mexico
• Dr. Arturo Reyes Sandoval, IPN and Oxford
• Dra. Cecilia Alpuche Aranda, INSP
• Dr. Carlos Arias Ortiz, IBT, UNAM, coordinador ProNaii Virología
• Dr. Carlos Crispin, INCMNSZ, coordinador ProNaii Inmunología
• Dr. Constantino López Macías, Siglo XXI, IMSS
• Dr. Gustavo Reyes Teherán. Coordinacion de Inst. Nac. Salud
• Dr. Alfredo Torres Tejeda, University of Texas
DEVELOPMENT OF A COVID19 VACCINE
IN MEXICO
 “PATRIA” (HOMELAND)
VACCINE DEVELOPED IN MEXICO

1 Newcastle viral vector has

SARS-CoV-2 S protein 3 Immune system
produces antibodies vs
COVID19 Spike

PHASE I TRIALS

Starting in may 2021

Leading mexican vaccine
2 Transduced cells in humans
produce SARS-CoV-2 Proteins
Thanks to
Prof. Dr. Ma. Elena Alvarez-Buylla
Director, CONACyT
ADVANTAGES OF THE NEWCASTLE VIRUS AS
VACCINE PLATFORM

Safe in humans. Studies >10 years.

High plasticity, useful as vaccine platform for

other pathotens

Newcastle is not present in humans, hence no

pre-existing immunity

It can be administered as nasal vaccine,

stimulating mucosal immune responses
MORTALITY BY AGE TO DEVISE A VACCINATION STRATEGY
IN MEXICO
Thanks to Dr. Celia Alpuche
COVID19 PANDEMIA AS AN OPPORTUNITY FOR IPN:
LNVYVT

 Construction of a National Laboratory of Vaccine development and

virus research at IPN
 BSL-3 laboratories to handle pathogens
 Animal facility
 Strategic position near BIRMEX and the National Institute for
Hygiene, both government facilities to produce vaccines
 Co-investment by CONACyT and IPN: Federal Government
 Internationalisation at IPN

Germany
Agreement with Servicio Alemán de Intercambio Académico
DAAD
1) General agreement
Aim Activities of mutual interest in science and technology

Date 19 Sep 2005, for 3 years

(Ended in 2008).
2) Specific agreement
Aim Student mobility between IPN and Germany, for science and
Ingeneering

Date 19 Sep 2005, for 5 years

Secretaría de Innovación e Integración Social (Ended in 2010).
 Current agreements with German Institutions

NO Institution Date Ending Type of agreement Aim

HOF University of
1 14/11/2018 14/11/2023 General agreement Activities of cooperation
Applied Sciences

HOF University of Specific agreement for

2 14/11/2018 14/11/2023 Undergraduate and graduate student mobility
Applied Sciences student mobility

Student mobility in areas of Engineering,

3 University of Stuttgart 07/01/2019 07/01/2023 Student exchange Architecture, Aeronautics, Civil, Computer,
Electric, Electronic and Mechanic engineerings.
Thriving scientific community at IPN

 Scientific publications co-authored

between IPN and German institutions

 395 with RWTH Aachen

 158 Bergische Universität Wuppertal

 135 LMU München

 135 with GAU Göttingen

 CONTACT DETAILS

Director General del IPN

Dr. Arturo Reyes Sandoval
http://www.ipn.mx/
Secretario de Innovación e Integración Social
M. en C. Ricardo Monterrubio López
siis@ipn.mx
Consultor Internacional
Dr. David Oliva Uribe
doliva@ipn.mx
Dirección de Relaciones Internacionales
IBQ. Raúl Maldonado Arellano
rmaldonado@ipn.mx